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ABSTRACT
CHARACTERIZATION AND KNOCKDOWN OF TATA-BINDING PROTEIN 1 IN
TOXOPLASMA GONDII
by
Malorie Nitz
University of New Hampshire, May, 2022
Toxoplasma gondii is a single celled eukaryotic parasite that causes the disease
toxoplasmosis, which infects approximately thirty to fifty percent of the world’s population.
Current treatments for toxoplasmosis are lacking and immunocompromised individuals are at
risk of a reactivation of acute infection. Tight control of transcription initiation is critical for
maintaining proper infection for the parasite. TATA-binding proteins (TBPs) are critical
transcription factors for recognizing and binding to the TATA-box and other motifs in
eukaryotes to recruit the transcription preinitiation complex. Toxoplasma contains two TBPs,
TgTBP1 and TgTBP2, but TATA-boxes or other conserved motifs have not yet been identified
in its promoter regions. Little is known about the role of TBPs in Toxoplasma. I hypothesize that
TgTBP1 and TgTBP2 bind to specific sequences within promoters, interact with the TFIID
complex, and are essential for parasite viability.
To investigate the role of TgTBP1 in Toxoplasma, I replaced the endogenous tgtbp1
promoter with a tetracycline regulatable promoter to knockdown tgtbp1. After successfully testing
the knockdown system, parasite phenotyping assays were performed. Intracellular plaque assays
show that TgTBP1 knockdown is lethal to parasites. Parasite doubling assays show that loss of
viii

TgTBP1 results in a significant delay in replication; however, immunofluorescence assays showed
that knockdown does not affect cell morphology or halt cell cycle progression, demonstrating that
TgTBP1 loss results in slowed progression through the cell cycle. Parasite invasion assays
exhibited a defect in host cell invasion upon TgTBP1 knockdown. As tgtbp1 expression decreases,
preliminary data shows that tgtbp2 expression increases, providing evidence that TgTBP2 may be
attempting to compensate for loss of TgTBP1. With this information, we begin to further narrow
down the role of TgTBP1 in transcription initiation and regulation in Toxoplasma gondii.
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CHAPTER I: INTRODUCTION
Toxoplasma gondii, a eukaryotic pathogen
The obligate intracellular parasite Toxoplasma gondii has the ability to infect virtually all
nucleated cells in warm blooded animals, including humans. Toxoplasma is a part of the phylum
Apicomplexa, which consists of medically relevant pathogens such as Plasmodium spp., the
causative agent of malaria, and Cryptosporidium spp., the causative agent of cryptosporidiosis.
Apicomplexans are most notably characterized by the apical complex, an instrumental structure
for host cell invasion, and once invaded survive inside a parasitophorous vacuole. These
organisms contain secretory organelles including rhoptries, micronemes, and dense granules to
aid in host cell adhesion and invasion (1).
Because Toxoplasma can infect most nucleated cells in mammalian organisms, the
pathogen is one of the world’s most common parasites. Worldwide seroprevalence of
Toxoplasma can vary from 10% to 98% depending on a countries socioeconomic and
environmental status (2). Approximately 60 million Americans are chronically infected with the
parasite and are at risk of a reactivation of acute infection. Toxoplasma is highly genetically
diverse, however the main lineages found in humans include type I, type II, and type III strains,
with type II being the most predominant in human and livestock infections (3). Type I strains are
highly virulent compared to type II and III, but cannot readily form bradyzoites, the chronic form
of Toxoplasma infection. Type II and III can maintain chronic infection and revert back to acute
infection upon immune system suppression (4).
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Toxoplasma Life and Lytic Cycle
Life Cycle
As an obligate intracellular parasite, Toxoplasma must always reside within a host cell to
survive. Although the parasite can infect any warm-blooded animal, the definitive hosts of
Toxoplasma are felines, meaning that sexual reproduction can only occur in the intestines of cats.
Felines lack the delta-6-desaturase enzyme in their intestines, which is required for linoleic acid
metabolism, causing an excess of linoleic acid and therefore promoting Toxoplasma sexual
reproduction (5). Transmission occurs when felines ingest prey containing Toxoplasma tissue
cysts; following ingestion, a proteolytic enzyme will dissolve the cyst walls, releasing
bradyzoites. The parasites progress through five stages of schizogony and eventually convert to
merozoites, which are responsible for invading the intestinal epithelium of the cat (6). Once the
parasites invade, they begin to differentiate into one of two forms of gametes: microgametes or
macrogametes. The fusion of a microgamete and macrogamete form an oocyst, which is released
into the intestinal lumen of the feline. These oocysts are shed from the cat within its feces; once
it matures in the environment, it can infect intermediate hosts through ingestion (Figure 1) (6).
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Figure 1. Life cycle of Toxoplasma gondii. Parasites reproduce asexually in felines, which excrete oocysts that are
found in water or soil. These are transmitted to intermediate hosts where the asexual portion of the life cycle begins.
This begins as an acute stage then converts to chronic tissue cysts, which persist throughout the life of the host.
Humans, as intermediate hosts, can also experience congenital toxoplasmosis, where acute tachyzoites cross the
placental wall and infect the fetus.

The asexual component of Toxoplasma’s life cycle occurs within intermediate hosts,
which are any warm-blooded animal including humans (Figure 2). When an intermediate host
ingests an oocyst, sporozoites are released and infect the intestinal epithelium of the intermediate
host. The sporozoites will differentiate into tachyzoites, which comprise the acute infection of
the parasite. Tachyzoites rapidly replicate inside a host cell, egress from the cell, and infect a
new one (7). In an immunocompetent host, the immune system will efficiently prevent the
replication of tachyzoites; this pressures tachyzoites to differentiate into bradyzoites, which
comprise the chronic infection of Toxoplasma in the form of tissue cysts (Figure 2) (7). Tissue
cysts are prevalent in the central nervous system, eyes, and muscle tissue. Tissue cysts contain
hundreds of bradyzoites and are less susceptible to proteolytic enzymes. They will remain in host
cells throughout the life of the host without causing an inflammatory response (8). At a slow rate,
bradyzoites can spontaneously differentiate back into tachyzoites. In a healthy host, the immune
system can eliminate these activated cells. However, in an immunodeficient host, a reactivation
3

of acute infection can result in deleterious effects on the central nervous system, ocular tissue,
and muscle tissue (9).

Figure 2. Asexual stages of Toxoplasma gondii, found in intermediate hosts. The acute stage consists of
tachyzoites, which rapidly replicate throughout the host. Upon immune system pressure, they differentiate
into chronic tissue cysts, which remain throughout the life of the host. These can spontaneously differentiate
or differentiate upon immune suppression, reactivating acute infection.

The two main routes of infection with Toxoplasma are oral and congenital (10). One
possible method of transmission of Toxoplasma in humans can occur through the ingestion of
tissue cysts found in undercooked meat, where the parasite is common in many animals used for
food (Figure 1) (11). The parasite can survive for years within animals as tissue cysts, and
therefore pose a threat for human infection. Humans can also become infected through ingestion
of oocysts through contaminated water or feline feces, which then differentiate into the asexual
form of the parasite in the host (11). Congenital toxoplasmosis occurs when a pregnant woman
has a primary infection with the parasite, where tachyzoites cross the placental wall and infect
the fetus (Figure 1). Depending on the gestational age, congenital toxoplasmosis can cause
damage of varying severity (9). Toxoplasma poses a serious threat to immunocompromised and
pregnant individuals.
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Lytic Cycle
The parasite proceeds through a complex lytic cycle to attach, invade, replicate, and
egress host cells to maintain infection (Figure 3). When Toxoplasma finds a host cell to invade,
the surface antigen protein SAG1, found on the protein coat of the parasite, recognizes
proteoglycans on the surface of the host cell (12). Once recognition occurs, microneme proteins
are secreted from the apical end of the parasite, which aid in forming an attachment to the host
cell and providing gliding motility to the parasite for host cell entry (13). A moving junction is
formed to mediate interactions between the parasite and the host cell. Once this is established,
rhoptry proteins are excreted from the apical end and invaginates the host cell plasma membrane.
As Toxoplasma enters the cell, a parasitophorous vacuole (PV) is formed, where the parasites
reside during replication (Figure 3). Rhoptry and dense granule proteins are secreted to alter the
PV membrane (PVM) to adapt to the host cytoplasm (14). Additionally, dense granule proteins
can enter the host cell from the parasite to modify the host cells response to infection (7).
Replication of Toxoplasma tachyzoites occurs by endodyogeny, where two daughter cells are
formed within a mother cell (15). Typically, tachyzoites will replicate within six to eight hours
(Figure 3). After several rounds of replication, egress is triggered by various mechanisms,
including a decrease in intracellular K+ and pH, and an increase in abscisic acid (ABA) (16).
Toxoplasma parasites rupture the PV and egress into the extracellular environment, where they
use gliding motility to continuously invade other host cells, repeating the lytic cycle (Figure 3).
Invasion, replication, and egress are complex components of parasite infection requiring
different molecular, cell, and biochemical processes; very tight regulation of gene expression is
required to maintain these processes and progress through Toxoplasma infection.
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Figure 3. Lytic cycle of Toxoplasma gondii. Extracellular parasites use specific proteins to aid in host cell
invasion, where they form a parasitophorous vacuole. Tachyzoites replicate within 6-8 hours inside the
parasitophorous vacuole. After several rounds of replication, the parasites lyse the host cell and egress,
beginning the lytic cycle again.

Clinical Presentation of Toxoplasma
In immunocompetent individuals, symptomatic infection of Toxoplasma is uncommon;
the immune system can quickly eliminate tachyzoites, and the parasites that differentiate into
latent bradyzoites will remain throughout the life of the host. Individuals who are symptomatic
may have muscle pain, headaches, or fever. Tissue cysts containing bradyzoites can develop in
organs such as the liver and lungs but are most prevalent in the eyes and central nervous system,
including the brain (8). While there are obvious effects of acute toxoplasmosis, less is known
about the long-term impact of chronic toxoplasmosis on human health. Studies on the
implications of chronic toxoplasmosis have found correlations between chronic infection and
behavior and mental disorders (17). Toxoplasma seropositivity has been associated with
disorders such as schizophrenia, epilepsy, and neurodegenerative diseases. However, there has
been no clear experimental evidence of a direct effect of Toxoplasma chronic infection on
neurological function (9).
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While asymptomatic infection is common in healthy individuals, Toxoplasma infection in
immunocompromised people can be severe. When an individual becomes immunocompromised,
latent bradyzoites can differentiate back into tachyzoites, causing a reactivation of acute
infection in organs where tissue cysts were residing. This can cause effects such as toxoplasmic
encephalitis, where parasites encysted in the central nervous system can cause great tissue
damage and inflammation (18). Other common symptoms include myocarditis, fever, ataxia, or
seizures (19). Ocular toxoplasmosis is a common presentation of reactivated acute infection,
which can cause damage to the ocular tissue and permanent eye damage (20). Reactivation of
Toxoplasma tachyzoites poses a major threat to immunodeficient individuals. In cases of
congenital toxoplasmosis, as the parasites infect the body, tachyzoites infect the uterus and cross
the placental wall, eventually infecting the fetus (10). This can have numerous serious
consequences, such as premature birth, eye infections, swollen organs and glands, or miscarriage
(21).
Drug treatments for Toxoplasma infection only treat the acute form of infection; there are
no available treatments for removal of chronic tissue cysts. The primary treatment for
toxoplasmosis includes a combination of sulfadiazine and pyrimethamine, which target the
dihydropteroate synthase (DHPS) and dihydrofolate reductase (DHFR) enzymes in the folic acid
synthesis pathway, respectively (22). DHFR is present in both humans and the parasite;
pyrimethamine has a slightly higher affinity for parasite DHFR, however it can still cause
toxicity in humans. Therefore, this combined treatment is typically supplemented with folinic
acid to reduce side effects of toxicity (22). Due to the toxic nature of pyrimethamine, pregnant
women are typically administered spiramycin as a nontoxic alternative that does not cross the
placental wall (22). There is an urgent need for better treatments for the acute and chronic form
7

of Toxoplasma infection that are more effective and safer for patients. Studying the biology of
Toxoplasma can reveal novel and unique pathways that can be targeted for therapeutic drugs.
Transcription Initiation and Regulation
Synthesis of a protein begins with transcription, the process of reading a DNA molecule
and creating an RNA transcript which then used for translation into a protein. Transcription of
protein-coding genes is performed by RNA polymerase II. The initiation of transcription occurs
in the promoter of a gene, an upstream region of a gene that contains binding sites for regulatory
elements and transcription factors (TF). RNA polymerase II transcription requires the presence
of several basal TFs, which recognize and bind to specific motifs in the promoter and form the
transcription preinitiation complex (PIC). In most eukaryotes, general TF’s TFIID, TFIIA,
TFIIB, TFIIE, TFIIF, and TFIIH form the PIC in a stepwise manner (Figure 4) (23). The first
step of initiation involves the recognition and binding of the TATA-binding protein (TBP) to a
motif in the promoter, which then recruits the rest of TFIID, TFIIA, and TFIIB (Figure 4). This
is followed by the recruitment of RNA polymerase II, TFIIF, TFIIE, and TFIIH, completing PIC
assembly (Figure 4). To proceed with RNA synthesis, the PIC must melt the promoter to insert
the template DNA strand, a process that is reliant on TFIIH to separate the strands, allowing
RNA polymerase access to the template (24). Once initiation is complete, elongation and
termination occur. Many components of the PIC are conserved across humans and yeast;
Toxoplasma possesses numerous PIC components; however, several proteins are not present
(Table 1). Little is known about the proteins that actively contribute to PIC formation in
Toxoplasma.
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Figure 4. Transcription preiniation complex formation. TBP recognizes the TATA-box or other initiator motifs in the promoter,
directly interacts with DNA with several amino acid residues and bends the DNA 80°, recruiting the TFIID complex. TFIID then
recruits the TFIIA and TFIIB complexes, followed by TFIIE, TFIIF, RNA polymerase, and TFIIH in a stepwise manner.

Table 1. PIC orthologs across humans, yeast, and Toxoplasma gondii. Protein sequences from Uniprot were
compared to the Toxoplasma ME49 strain using BLAST (NCBI) in ToxoDB (25).

Transcription
Factor

Homo sapiens

Saccharomyces
cerevisiae

Toxoplasma gondii

Gene ID

hypothetical protein

TGME49_259580

hypothetical protein

TGME49_232210

--TFIIB

TGME49_292010

TFIIA subunit 1 α
TFIIA

TOA1

TFIIB

TFIIA subunit 2 α/ Γ
TFIIA Γ
TFIIB

TFIID

TAF1
TAF2
TAF3
TAF4
TAF5
TAF6
TAF7
TAF8
TAF9

TFIIE
TFIIF

TOA2
TFIIB (SUA7
gene)
TAF1/145
TAF2/150
TAF3/47
TAF4/48
TAF5/90
TAF6/60
TAF7/17
TAF8/65
TAF9/17

TAF9B
TAF10
TAF11
TAF12
TAF13
-TAF15
TBP

-TAF10/25
TAF11/40
TAF12/61-68
TAF13/19
TAF14
--

TFIIEα/ GTF2E1
TFIIEβ
TFIIFα
TFIIFβ
TFIIH helicase
subunit XPB

TFA1
TFA2
TFG1
TFG2
SSL2
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TAF1/250
TAF2/150
--TAF5
TAF6
TAF7
TAF8
TAF9
hypothetical protein
-hypothetical protein
-TAF12
---TBP1
TBP2
GTF2E1
hypothetical protein
-membrane protein
TFIIH helicase
subunit XPB

TGME49_276180
TGME49_214240

TGME49_318260
TGME49_295410
TGME49_309170
TGME49_313810
TGME49_233400
TGME49_246670
TGME49_315120
TGME49_244160

TGME49_291080
TGME49_258680
TGME49_231010
TGME49_203358
TGME49_281950
TGME49_269660

TFIIH

TFIIH helicase
subunit XPD
TFIIH subunit 1
(p62)
TFIIH subunit 2
(p44)
TFIIH subunit 3
(p34)
TFIIH subunit 4
(p52)
TFIIH subunit 5

RAD3

MAT1
CDK7

TFB3
KIN28

CCL1

CCL1

TFB1
SSL1
TFB4
TFB2
TFB5

TFIIH helicase
subunit XPB,
putative
DNA excision repair
helicase
--

TGME49_302450

TFIIH polypeptide 2
GTF2H2
TFIIH polypeptide 3
GTF2H3
TFIIH polypeptide 4
GTF2H4
TFIIH polypeptide 5
GTF2H5
MAT1
cyclin H family
protein
cell-cycle-associated
protein kinase CDK

TGME49_294920

TGME49_216870

TGME49_266930
TGME49_214520
TGME49_217450
TGME49_320070
TGME49_260250
TGME49_218220

Gene regulation is a critical process that works with transcription factors to activate or
repress transcription. Regulation of gene expression primarily occurs at the initiation level.
Activator and repressor proteins regulate the rate of transcription of most genes (26). Activator
proteins bind to specific sites termed enhancers to induce transcription. Repressors work in a
similar manner but inhibit transcription from occurring. Eukaryotes such as humans and yeast
contain the Mediator, a large protein complex that is required for transcription in many RNA
polymerase II promoters. The Mediator acts similarly to a general TF, interacting with the PIC as
a coactivator to successfully begin RNA synthesis (27). There is no established Mediator
complex in Toxoplasma, although some parasite proteins with homology to certain subunits of
Mediator have been identified in the genome. An additional layer of gene regulation is chromatin
structure; DNA is tightly wrapped around an octamer of histones, forming the nucleosome, the
basic unit of chromatin (28). Changes in the structure of chromatin alter the availability of a
DNA template for transcription (26). Additionally, histone modifications such as acetylation,
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methylation, and phosphorylation mark genes for activating or repressing transcription, and help
recruit transcription complexes (28).
Regulation of gene expression is an integral process to maintain eukaryotic cells and
organisms. In protozoan pathogens, gene regulation has been shown as an essential pathway for
development and pathogenesis. Regulation of gene expression in Toxoplasma is largely
influenced by epigenetic mechanisms and by ApiAP2 APETELA plant-like proteins (AP2), a
family of transcription factors found in Apicomplexa (29).
The PIC binds to specific sequences upstream of the transcription start site known as
motifs. The most well-known motif is termed the TATA-box, containing a consensus sequence
of “TATAWAWR”, where “W” can be an adenine or thymine base, and “R” can be an adenine
or guanine base. The TATA-box is typically located approximately 30 base pairs upstream of the
transcriptional start site. The TATA-box is highly conserved amongst higher eukaryotes (30).
Other common motifs include the initiator element (Inr), which directly overlaps the
transcriptional start site, and the downstream promoter element, which is found following the
transcriptional start site (31). While these are the most commonly recognized motifs, each
eukaryotic organism can contain many varying consensus motifs within their promoters.
TATA-Binding Proteins
A vital protein for the formation of the PIC is TBP, whose role is to bind to the TATAbox or other initiator motifs to begin recruiting the PIC (32). TBP is a small, saddle-shaped
protein containing minor and major grooves whose structure is highly conserved. TBP is a part
of the TFIID complex, which includes several TBP-associated factors (TAFs). TBPs contain a Cterminal domain that helps recognize and bind DNA in a sequence-specific manner; several
11

amino acid residues contribute to DNA binding, bending the DNA 80° and allowing the
recruitment and stabilization of the PIC and RNA polymerase (33). The concave region of TBP
binds to DNA and the convex portion is available for cofactor binding (34). TFIIA and TFIIB
directly interact with TBP to stabilize the DNA-TBP complex at promoters (35). Most
eukaryotes contain a single TBP that is constitutively active in all cell types.
Since TBPs are essential for PIC formation, recruitment of TBP to template DNA could
be a rate-limiting step in transcription initiation. In humans and yeast, TBP is largely present as a
dimer when not bound to DNA. Dissociating from the dimer is a slow kinetic process, which is
another regulating mechanism of gene expression (36). Dimerization of TBPs competes with
DNA binding, suggesting that TBP homodimers are a mechanism for negatively regulating DNA
binding activity. Additionally, there is a relationship between TBP and the SAGA complex,
found in humans and yeast. The SAGA complex is a multi-protein chromatin remodeling
complex and is associated with activation of transcription. The Spt3, Spt7, and Spt8 subunits of
the SAGA complex bind to and deliver TBP to promoters to nucleate formation of the PIC,
regulating the initiation of gene expression (37,38). A conserved SAGA complex has not been
identified in Toxoplasma (39). Negative cofactor 2 (NC2) is a negative regulator of basal
transcription through direct TBP interaction. NC2 inhibits transcription through binding of TBP,
blocking the recruitment of TFIIA and TFIIB and thereby inhibiting PIC assembly (40). An NC2
ortholog does not exist in Toxoplasma. TAF1, a factor in the TFIID complex, can also negatively
regulate transcription via interaction with TBP. The TAF1 N-terminal domain (TAND), which is
comprised of TAND1 and TAND2, interact with the concave and convex surfaces of TBP,
respectively. TAND1 interacts directly with TBP, blocking TBP-DNA binding to the promoter;
TAND2 interacts with TBP to inhibit TFIIA-TBP interaction, prohibiting recruitment of the PIC
12

(41). A TAF1 protein exists in Toxoplasma, but its ability to bind TBP and regulate transcription
is unknown.
TBPs have been identified and studied in several protozoan pathogens including C.
parvum, P. falciparum, and Entamoeba histolytica (35). C. parvum contains a TBP protein that
binds DNA in vitro; electrophoretic mobility shift assays (EMSA) with recombinant CpTBP
have shown that the protein can bind a bacterial TATA-box consensus sequence. Furthermore,
CpTBP interacts with multiprotein bridging factor type 1 (MBF1), a transcriptional coactivator
that is known to enhance gene expression (42). P. falciparum contains a single TBP protein that
has been shown to recognize a TATA-box sequence and TATA-box-like sequence (TGTAA) in
two Plasmodium promoters via EMSA and chromatin immunoprecipitation (ChIP) experiments
(43,44). However, PfTBP is bound to DNA in transcriptionally inactive genes, suggesting that
PfTBP may be pre-assembled at DNA and other cofactors are needed for PIC formation (45). E.
histolytica contains two TBPs, EhTBP1 and EhTBP2; EhTBP2 is identical to EhTBP1 and is
silenced by genomic DNA methylation (46). E. histolytica also contains a TBP-related factor 1
(EhTRF1) that shares significant similarity to EhTBP1. E. histolytica contains several promoter
motifs including the TATA-box and GAAC-box. It has been shown that EhTBP1 and EhTRF1
bind to the TATA-box, several TATA-box variants, and the GAAC-box in vitro (47,48). While
the DNA-binding capability of TBPs in several protozoans in-vitro is known, little is known
about TBPs in Toxoplasma.
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TBPs in Toxoplasma
While many eukaryotes contain a single universal TBP, Toxoplasma contains two TBPs:
TgTBP1 and TgTBP2. While this is peculiar, it is even more interesting to note that there have
been no TATA-box consensus sequences found in Toxoplasma. Additionally, Toxoplasma’s
Type I RH strain genome has a relatively high GC-content of 52%, making it less likely for a
TATA-box sequence to appear in the genome (49). Studies have shown that while there are
upstream elements that are required for several genes’ expression, no consensus initiation motifs
throughout Toxoplasma’s entire genome have yet been defined (50). Certain motifs have been
described for specific gene subsets; for example, the transcription factor BFD1 binds to a
CACTGG motif in many bradyzoite-specific genes (51). The GAGACGC motif has been
identified in 20.4% of tachyzoite stage-specific gene promoters, but a binding transcription factor
has not yet been identified. Little is known about Toxoplasma TBPs DNA binding properties,
their overall function, and their role in parasite fitness and survival. Relative fitness scores of
TgTBP1 and TgTBP2 calculated from a genome wide CRISPR/Cas9 screen are -4.81 and -3.73
respectively, strongly suggesting that these proteins are essential for parasite viability1 (52).
It is unknown if and how TBPs are regulated in Toxoplasma. The lack of a SAGA
complex and Mediator suggests that the parasite may rely more heavily on TFIID for recruitment
of the PIC. It is crucial to gain more information about these proteins, how they function, and
how they are regulated to determine if they play a significant role in transcription initiation in
Toxoplasma. Understanding the basal transcriptional machinery is vital for fully understanding

1.

This study utilized genome wide CRISPR/Cas9 to assess the contribution of each gene in Toxoplasma
during infection. Scores range from -6.98 to 2.96, with lower values conferring to higher essentiality for
parasite fitness.
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how the parasite expresses its genes; detecting unique components in the initiation process could
be useful for identifying anti-parasitic drugs for treating toxoplasmosis. I hypothesize that
TgTBP1 and TgTBP2 binds to specific sequences within promoters, interacts with the
TFIID complex, and is essential for parasite viability. I will address this hypothesis with the
following aims: Aim 1. Determine the DNA binding capability of TgTBP1 and TgTBP2. Aim 2.
Determine the impact of TgTBP1 and TgTBP2 expression on tachyzoite fitness. Aim 3.
Determine the interactome of TgTBP1 and TgTBP2.
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CHAPTER II: METHODS
Host cell and parasite culture
Primary human foreskin fibroblast (HFF) cells were cultured in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% heat inactivated fetal-bovine serum (FBS).
Toxoplasma Type I RH strain parasites lacking ∆Ku80 (∆Ku80) and Type I RH strain parasites
containing a tetracycline-controlled transactivator (TATi) were grown in confluent monolayer of
HFF cells in DMEM supplemented with 1% heat inactivated FBS. Host cell and parasite cultures
were maintained at 37 °C and 5% CO2.
Plasmid construction
To produce recombinant TgTBP1 protein in E. coli, an expression plasmid construct was
created with tgtbp1 fused to an N-terminal GST tag. The protein was expressed in E. coli and
purified using FPLC. In order to clone the coding region of tgtbp1 into the plasmid construct,
RNA was isolated and complimentary DNA (cDNA) was produced. Fully lysed ∆Ku80 parasites
from a T-25 flask were harvested, spun down, and washed with 1X PBS. RNA was isolated from
the pellets using phenol:chloroform. Briefly, TRI Reagent® (Sigma-Aldrich) was added to the
parasite pellet and incubated at room temperature. Chloroform was added to the solution,
incubated at room temperature, then centrifuged at 16,000xg for fifteen minutes at 4 °C. The
clear aqueous layer was transferred to a new tube, isopropanol was added to the solution,
incubated at room temperature, then centrifuged at 16,000xg for ten minutes at 4 °C. The
supernatant was removed, and the RNA was washed with 70% ethanol and centrifuged at
7500rpm for five minutes at 4 °C. The RNA pellet was dried, and the TURBO DNA-free™ Kit
(Invitrogen) was used to remove any DNA contamination from the sample. Complimentary
16

DNA (cDNA) was generated with tgtbp1-specific primers (primers 1 and 2, Table 3) using the
Omniscript RT Kit following manufacturer’s instructions (Qiagen). The DNA binding domain of
tgtbp1 was PCR amplified in two separate pieces using primers 3 and 4 for the first half and 1
and 5 for the second half of the sequence (Table 3) because amplification of the entire sequence
was unsuccessful. Assembly PCR was performed to amplify both pieces of the DNA binding
domain of tgtbp1 together using primers 6 and 7 (Table 3) containing a 14 base pair sequence of
homology to the target site of the pGEX-4T-1 plasmid on either end. Digestion of the pGEX-4T1 plasmid was performed overnight at 37 °C with EcoRI to linearize the plasmid before cloning
and was gel purified using the Monarch® DNA Gel Extraction Kit (New England BioLabs). The
tgtbp1 DNA binding domain sequence was inserted into the linearized pGEX-4T-1 plasmid at
the EcoRI site (939) using the NEBuilder® HiFi DNA Assembly Cloning Kit (New England
BioLabs) for expression of TgTBP1 fused to an N-terminal GST tag according to manufacturer’s
instructions.
To construct a plasmid with TgTBP1 fused to the enzyme TurboID, tgtbp1 genomic
DNA (gDNA) was cloned into a plasmid containing a TurboID-V5-HA tag to integrate into the
parasite genome. gDNA was extracted from fully lysed ∆Ku80 parasites using the DNeasy Blood
& Tissue Kits (Qiagen) following manufacturer’s guidelines. tgtbp1 gDNA was PCR amplified
using primers 8 and 9 (Table 3) to amplify a 1.5kb C-terminal piece of tgtbp1. The pTKO2-II-3MyoF-Turbo-V5-HA plasmid (a gift from Dr. Aoife Heaslip, UConn) was digested overnight at
37 °C using AvrII and BglII for linearization and gel purified using the Monarch® DNA Gel
Extraction Kit (New England BioLabs). The tgtbp1 sequence was inserted into the linearized
pTKO2-II-3-Turbo-V5-HA plasmid at the AvrII and BglII site (2844) using the NEBuilder®
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HiFi DNA Assembly Cloning Kit (New England BioLabs) for expression of tgtbp1 fused to
TurboID-V5-HA according to manufacturer’s instructions.
To construct a plasmid for regulation of tgtbp1 expression using a tetracycline inducible
knockdown system, tgtbp1 gDNA was cloned into a plasmid containing a tetracyclineregulatable promoter and myc tag. gDNA was isolated from fully lysed ∆Ku80 parasites using
the DNeasy Blood & Tissue Kits (Qiagen) according to manufacturer’s instructions. A 1.5kb Nterminal piece of tgtbp1 gDNA was PCR amplified using primers 10 and 11 (Table 3). The
DHFR-tetO7Sag4-myc-TgBDP1 plasmid was linearized overnight at 37 °C with NotI and BglII
and was gel purified using Monarch® DNA Gel Extraction Kit (New England BioLabs). The
tgtbp1 sequence was inserted into the linearized DHFR-tetO7Sag4-myc plasmid at the NotI and
BglII site (685) using the NEBuilder® HiFi DNA Assembly Cloning Kit (New England
BioLabs) according to manufacturer’s guidelines.
The recombined products of each cloned plasmid construct were transformed into NEB®
DH5-α competent E. coli cells (New England BioLabs). The competent cells and DNA mixture
were incubated on ice for thirty minutes, heat shocked to create pores in the membrane of the
bacteria allowing the plasmid DNA in, then returned to ice. The cells were grown for one hour in
SOC Outgrowth Media (New England BioLabs), then plated in a lawn on an LBA plate and
grown overnight at 37 °C.
Isolated colonies of the transformed bacteria were picked and grown in LBA broth
overnight at 37 °C. To identify a clone containing the integrated plasmid construct, small scale
plasmid purifications were performed. First, the bacteria were pelleted, and the media was
removed; the pellet was resuspended in a buffer containing 50mM Tris-Cl, 10mM EDTA, RNase
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A, pH 8.0. The bacteria were lysed in a buffer containing 200mM NaOH and 1% SDS, then
neutralized in 3M potassium acetate, pH 5.5 to separate the insoluble material. The sample was
spun down, and the liquid soluble material was transferred to isopropanol and incubated at room
temperature. The DNA was spun down and washed with 70% EtOH and dried at room
temperature. Purified plasmid DNA was resuspended in double deionized water.
Plasmid construct integration was confirmed by restriction digests and Sanger sequencing
from GeneWiz. Primers flanked the insert and alignments were performed on the sequenced
plasmid and the designed plasmid construct to confirm integration. Primers 12 and 13 were used
to confirm integration in pGEX-4T-1, primers 14 and 15 were used to confirm integration in
pTKO2-II-3-TurboID-V5-HA and primers 16 and 17 were used to confirm integration in DHFRtetO7Sag4-myc (Table 3). Once integration was confirmed, large scale plasmid purifications
were performed using the GenEluteTM HP Plasmid Maxiprep Kit (Sigma-Aldrich) with some
changes. The spin format was followed according to the manufacturer’s protocol. After eluting
the DNA, 0.3M sodium acetate and 100% ethanol was added to the DNA, then incubated at 20°C overnight. The DNA was centrifuged at 5,000xg for thirty minutes, the supernatant was
discarded, and the precipitated DNA was washed with 70% ethanol. After centrifugation, the
DNA pellet was dried then resuspended in 200-400 μL of water.
Transfection and drug selection
To prepare plasmid constructs for transfection, plasmids were linearized using a
restriction enzyme for insertion into the Toxoplasma gene locus using single-crossover
homologous recombination. The pTKO2-II-3-TgTBP1-Turbo-V5-HA plasmid was linearized
using CspCI for integration of the construct at the C-terminal end of the tgtbp1 gene locus. The
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DHFR-tetO7Sag4-myc-TgTBP1 plasmid was linearized using NheI for integration of the
construct at the tgtbp1 gene locus to replace the endogenous tgtbp1 promoter with the
tetracycline-regulatable Sag4 promoter. Five to ten micrograms of DNA was linearized overnight
at 37 °C. DNA purification of the linearized plasmid was performed by adding an equal amount
of phenol:chloroform:isoamyl alcohol (IAA) to the digested DNA, vortexing, and centrifuging.
The top layer was placed into a new tube and an equal volume of chloroform was added,
centrifuging once again. This was repeated a total of three times, and the DNA transferred to a
new tube after the third spin was precipitated by adding 2x volume of 100% EtOH and 0.1
volumes of 3M sodium acetate. The tube was incubated at -20 °C overnight. The DNA was then
centrifuged for thirty minutes at 4 °C. The supernatant was removed, and the DNA pellet was
washed with 70% EtOH and centrifuged. The DNA pellet was dried in the flow hood, then
resuspended in 20 uL of P3 Primary Cell Solution (Lonza).
Type I RH∆Ku80 parasites were used for transfection of pTKO2-II-3-TgTBP1-TurboV5-HA containing a disruption in the Ku80 gene to promote homologous recombination (53).
Type I RH∆Ku80 TATi parasites were used for transfection of DHFR-tetO7Sag4-myc-TgTBP1
containing a tetracycline-controlled transactivator (TATi) to bind to the tetO7 promoter at the
tgtbp1 locus (54). One mL of extracellular parasites was pelleted down, the media was removed,
and the resuspended DNA in transfection buffer was added to the pelleted parasites. The DNAparasite mix was placed into a 16-well strip and the 4D-Nucleofector® X Unit (Lonza) was used
for transfection with settings FI 115. Once transfection was complete, the parasites were added to
a T-25 flask containing an HFF monolayer 1% FBS DMEM.
Drug selection was commenced 24-48 hours after transfection to allow parasites to
recover and begin expressing the selection marker. The DHFR-tetO7Sag4-TgTBP1 parasite line
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was supplemented with 1uM pyrimethamine. This line contained the DHFR cassette within the
plasmid construct, which makes the parasite line resistant to pyrimethamine treatment. The
DHFR cassette contains three point mutations conferring resistance to pyrimethamine, which
normally kills parasites (55). The pTKO2-II-3-TgTBP1-Turbo-V5-HA parasite line was
supplemented with 25ug/uL mycophenolic acid (MPA) and 50ug/uL xanthine in 100uM KOH.
This line contains a hypoxanthine phosphoribosyl transferase (HXGPRT) cassette within the
plasmid construct, which makes the parasite line resistant to MPA/Xanthine treatment. The
HXGPRT cassette allows parasites to bypass inosine-5’-monophosphate dehydrogenase pathway
inhibition and convert xanthine to xanthosine monophosphate (56). Genomic PCR and
immunofluorescence assays were used to confirm integration of the plasmid construct into the
tgtbp1 gene locus.
Parasite cloning
Following several rounds of drug selection, uncloned parasite populations were diluted to
isolate single parasite clones to identify ones with correct genomic construct integration.
Parasites were counted using a hemocytometer. Calculations were performed to determine the
volume of a 1:1000 dilution of parasites needed to obtain one parasite per well in a 96-well plate.
Parasites were diluted 1:1000 in 10 mL of 1% FBS DMEM media and the calculated volume was
added to 20mL 1% FBS DMEM media containing the parasites corresponding drug needed for
selection. Two hundred uL of media was added to each well and cultured, undisturbed for five to
seven days at 37 °C and 5% CO2. After incubation, each well was checked using light
microscopy to identify wells with one plaque; clonal parasites from the wells containing one
plaque were screened for correct plasmid integration using the Phire™ Tissue Direct PCR
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Master Mix (Thermo Scientific) following manufacturer’s protocol with uncloned positive
populations and ∆Ku80 parasite gDNA as positive and negative controls, respectively.
Immunofluorescence assays (IFA)
Parasites were inoculated and grown in confluent HFF monolayers on coverslips in 12well plates for approximately twenty-four hours. To detect biotinylation in the pTKO2-II-3TgTBP1-Turbo-V5-HA parasite line, cells were incubated with 1% FBS DMEM media
containing 150uM biotin for one hour before fixing. Infected cells were fixed with 4%
paraformaldehyde in 1X PBS, then washed with 1X PBS three times. Cells were permeabilized
with 0.2% Triton X-100 in 3% BSA then washed with 1X PBS. Blocking was done with 3%
BSA for at least one hour at room temperature or overnight at 4 °C. Cells were incubated in
primary antibody in 3% BSA for two hours at room temperature or overnight at 4 °C (Table 2).
For the TgTBP1-Turbo-V5-HA parasite line, rat anti-HA was used. For the tet-myc-TgTBP1
parasite line, mouse anti-myc was used. To detect acetylated-α-tubulin, mouse anti-acetylated-αtubulin was used (Table 2). After primary antibody incubation, cells were washed three times in
1X PBS. Cells were incubated in secondary antibody and DAPI to stain the nucleus at 1:1000
dilution in 3% BSA for one hour at room temperature in the dark. For cells containing an antiHA primary antibody, they were incubated in anti-rat Alexa Fluor 594. For cells containing an
anti-myc or anti- acetylated-α-tubulin primary antibody, they were incubated in anti-mouse
Alexa Fluor 594. To detect biotinylation in TgTBP1-Turbo-V5-HA parasites, cells were
incubated in Streptavidin Alexa Fluor 488 (Table 2). After secondary antibody incubation, cells
were washed with 1X PBS. Coverslips were mounted face down onto a microscope slide with
VECTASHIELD Antifade Mounting Medium and viewed under a fluorescent microscope.
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Western Blot
To produce protein lysate for Western blotting, a heavily infected monolayer of parasites
was scraped to release parasites from host cells, pelleted, and the media was removed. Parasites
were resuspended in RIPA buffer (50mM Tris HCl, pH 7.9, 150mM NaCl, 1% NP-40, 0.5%
sodium deoxycholate, 0.1% SDS) supplemented with 1X protease inhibitor cocktail (PIC).
Parasite lysates were kept on ice and sonicated for two minutes at 50% amplitude, then stored at
-20 °C. Protein quantification was performed using the Pierce™ BCA Protein Assay Kit
according to manufacturer’s instructions using the microplate procedure (Thermo Scientific).
Fifty to one hundred μg of sample lysate were added to each Western Blot in equal
concentrations across each sample. Samples containing protein lysate, 4X NuPAGE™ LDS
Sample Buffer, and β-mercaptoethanol were run on denaturing NuPAGE™ 4-12% Bis-Tris
polyacrylamide gels (Invitrogen). Gels were transferred to a nitrocellulose membrane and stained
with Ponceau S to verify complete protein transfer. Blots were blocked in 5% BSA or 5% nonfat milk overnight at 4 °C. HA-tagged proteins were probed with a rat anti-HA primary antibody
(Table 2). After primary antibody incubation, blots were washed three times with Tris-buffered
saline Tween 20 (TBST). Myc-tagged proteins were probed with mouse anti-myc horseradish
peroxidase (HRP). Anti-rat antibody conjugated to HRP (GE NA935, 1:2000) was used as a
secondary antibody for anti-HA blots (Table 2). To probe for biotinylation of proteins, blots were
incubated in streptavidin-HRP conjugate (Table 2). Secondary antibodies were incubated for one
hour at room temperature, then washed three times with TBST. Blots were visualized using the
Chemiluminescence Western Blot Substrate (Pierce) and imaged using the BioRad V3
Chemidoc.
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Table 2. Primary and secondary antibodies used for IFA, Western blotting, and invasion assays.

Primary Antibodies

Secondary
Antibodies

Primary Antibodies
Secondary
Antibodies

IFA Antibodies
Antibody
Dilution
Rat anti-HA (Roche 27573500)
1:2000 in 3% BSA
Mouse anti-myc (Invitrogen 132500)
1:2000 in 3% BSA
Mouse anti-acetylated-α-tubulin (Sigma
1:1:000 in 3% BSA
T7451)
Mouse anti-P30/SAG1 (Invitrogen
1:2000 in 3% BSA
MA183499)
Rabbit anti-Toxoplasma (Invitrogen
1:1000 in 3% BSA
PA17252)
Goat anti-rat Alexa Fluor 594 (Thermo
1:5000 in 3% BSA
Scientific A11007)
Goat anti-mouse Alexa Fluor 594
1:5000 in 3% BSA
(Thermo Scientific A11005)
Streptavidin Alexa Fluor 488 (Invitrogen 1:1000 in 3% BSA
S32354)
Goat anti-mouse Alexa Fluor 488
1:5000 in 3% BSA
(Thermo A11001)
Goat anti-rabbit Alexa Fluor 594
1:5000 in 3% BSA
(Thermo A11012)
Western Blot Antibodies
Antibody
Dilution
Rat anti-HA (Roche 27573500)
1:2000 in 5% non-fat milk
Mouse anti-myc-HRP (Santa Cruz sc-40)
1:100 in 5% non-fat milk
Anti-rat-HRP (GE NA935)
1:2000 in 5% non-fat milk
Streptavidin-HRP (Invitrogen S911)
1:2000 in 5% BSA

qRT-PCR
RNA was isolated using phenol:chloroform as previously described above. RNA was
denatured at 70 °C for five minutes then chilled on ice for at least five minutes. cDNA was
synthesized using the OmniScript RT Kit according to manufacturer’s protocols. Real-time PCR
reactions were prepared using the Power SYBR® Green PCR Master Mix (Applied Biosystems).
To detect expression of tgtbp1, primers 18 and 19 were used. To detect expression of TurboID,
primers 20 and 21 were used. To detect expression of tgtbp2, primers 22 and 23 were used. αtubulin was used as an endogenous control with primers 24 and 25 (Table 3). Reactions were set
up and cycled according to manufacturer’s protocol for MicroAmp 0.1ml Fast Optical 96-well
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plates. The plate was heated to 52 °C for twenty seconds, then held at 95 °C for ten minutes. The
plate was then cycled at 95 °C for fifteen seconds and cooled to 60 °C for one minute for forty
cycles. The melt curve step included heating the plate back to 95 °C for fifteen seconds, then
held at 60 °C for one minute, then heated back to 95 °C for thirty seconds. Finally, the plate was
cooled to 60 °C for fifteen seconds. The Applied Biosystems 7500 Fast Real-Time PCR System
was used to perform qRT-PCR.
Protein Expression and Purification
The pGEX-T-1-TgTBP1 plasmid was transformed into BL21 (DE3) competent (Thermo
Scientific EC0114) E. coli cells and plated as a lawn on an LBA plate overnight at 37 °C. A
single colony was picked and grown in LBA broth overnight at 37 °C until turbid. Preculture was
added to 500mL fresh LBA at a 1:250 dilution and grown to an OD600 of 0.6-0.8 and incubated in
100mM isopropyl β-D-1-thiogalactopyranoside (IPTG) for fifteen hours at 15 °C to induce
expression of GST-TgTBP1 protein. The bacteria were pelleted at 20,000xg for twenty minutes
at 4 °C; the media was removed, and the pellets were stored at -80 °C for at least one hour. The
pellets were resuspended in a lysis buffer containing 150mM HEPES, 150mM NaCl, pH 7.6 with
1X protease inhibitor cocktail and benzonase. The lysate was mechanically lysed three times at
1750 psi using a French Press G-M® (GlenMills) with a 40kpsi cell. The lysate was spun for
twenty minutes at 20,000xg at 4 °C and the soluble material was removed for purification.
GST-TgTBP1 protein was purified using fast protein liquid chromatography (FPLC) with
Pierce™ Glutathione Chromatography Cartridges. The protein was washed using a buffer
containing 50mM Tris, 150mM NaCl, pH 8.0. The protein was eluted using a buffer containing
50mM Tris, 150mM NaCl, 10mM glutathione, pH 8.0. Buffer exchange was performed to
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remove glutathione from the purified protein sample using the Zebra Spin Desalting Column
(Thermo Scientific).
Protein quantification was performed using the Pierce™ BCA Protein Assay Kit
according to manufacturer’s instructions using the microplate procedure (Thermo Scientific).
Standards were made using the GST wash buffer previously described above.
Preparation of parasite nuclear extracts
Nuclear extracts were prepared by harvesting ∆Ku80 parasites and washing them with
cold PBS. The pellet was resuspended in four mL of nuclear extract buffer A containing 10mM
HEPES pH 7.9, 1.5 mM MgCl2, 10mM KCl, 0.5mM DTT, 0.1mM EDTA, 0.65% NP-40,
0.5mM PMSF. Parasites were incubated on ice for ten minutes, then centrifuged at for ten
minutes at 1,500xg at 4°C. The supernatant containing cytoplasmic extracts was removed and the
nuclear pellet was resuspended in 400 μL of nuclear extract buffer B containing 20mM HEPES
pH 7.9, 1.5mM MgCl2, 420mM NaCl, 0.2mM EDTA, 0.5mM DTT, 25% glycerol, 0.2mM
PMSF. This was incubated on ice for fifteen minutes, then centrifuged at 14,000xg for ten
minutes at 4°C. The supernatant contained nuclear extracts and was stored in aliquots at -80°C.
Protein quantification performed using the Pierce™ BCA Protein Assay Kit according to
manufacturer’s instructions using the microplate procedure (Thermo Scientific). Standards were
made using the nuclear extract buffer B.
In vitro binding assays (EMSA)
The LightShift™ Chemiluminescent EMSA Kit was used to perform electrophoretic
mobility shift assays (Thermo Scientific). Five to fifteen micrograms of recombinant TgTBP1
protein or five micrograms of nuclear extract were combined with 200fmol of biotin-labelled
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double-stranded oligonucleotides (Table 4), 10X binding buffer, and Poly(dl·dC). Provided
control reactions were performed with each assay using EBNA extract and biotin-labelled DNA.
Binding reactions were incubated at room temperature for twenty minutes, then run on a pre-run
6% polyacrylamide gel. The gel was transferred to a nylon membrane and the DNA was
crosslinked to the membrane using 254nm UV light. The membrane was incubated in blocking
buffer for fifteen minutes, then incubated in a streptavidin-HRP conjugate in blocking buffer for
fifteen minutes. The blot was then washed with 1X wash buffer, then incubated for five minutes
in a substrate equilibrium solution. The membrane was visualized using equal parts of the
provided working solutions for five minutes and imaged using the BioRad V3 Chemidoc.
Parasite Phenotyping Assays
To measure the parasites’ ability to successfully invade, replicate, and egress from host
cells upon TgTBP1 knockdown, plaque assays were performed. A heavily infected monolayer of
intracellular parasites in a T25 flask was syringe lysed and counted. Parasites diluted to
approximately 100 parasites per mL were added to a confluent monolayer of HFFs in a 12-well
plate. Media contained pyrimethamine for drug selection. Parasites were grown with and without
anhydrotetracycline (ATc) in triplicate. The plates grew undisturbed for 5 days at 37 ℃ in 5%
CO2. Plates were then washed with PBS and fixed with cold methanol. Wells were stained with
Crystal Violet to view plaques then washed with PBS. Plates were imaged with the BioRad
Chemidoc V3. Plaque assays were performed in triplicate.
To measure parasite replication following TgTBP1 knockdown, doubling assays were
conducted. Tet-myc-TgTBP1 and TATi parasites were grown with and without ATc in separate
T25 flasks for twenty-four hours. Extracellular parasites were removed, and intracellular
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parasites were harvested by scraping, resuspended in media, and syringe lysed. Five μL of
parasites were added to three wells in a 12-well plate. The parasites were incubated at 37 ℃ in
5% CO2 for two to four hours to invade host cells, then the media and extracellular parasites
were removed, and the monolayer was rinsed with media and replaced with media containing
pyrimethamine, and either with or without ATc. Individual wells were grown then fixed with
cold methanol after twelve, twenty-four, and thirty-six hours for each population. Staining of
parasites was performed using the Hema 3™ Manual Staining System (Fisher Healthcare), and
the number of parasites in 100 vacuoles was counted for each population at each timepoint using
light microscopy. Doubling assays were performed in triplicate.
To assess the parasites’ ability to invade host cells after loss of TgTBP1, invasion assays
were performed. Tet-myc-TgTBP1 and TATi parasites were pretreated with and without ATc in
separate T25 flasks for thirty-six hours. Extracellular parasites were removed, and intracellular
parasites were harvested by scraping, resuspended in media, and syringe lysed. Parasites were
counted using a hemocytometer, then diluted to 1x106 parasites/mL in chilled DMEM media
containing 1% FBS with or without ATc. Parasites were inoculated into wells containing HFF
cells on coverslips and incubated on ice for fifteen minutes. The plate was incubated in a 37℃
water bath for one minute, then incubated for two hours at 37℃ and 5% CO2. The media was
removed, and the wells were washed with 1X PBS. The cells were fixed with 3%
paraformaldehyde for fifteen minutes, then blocked for one hour in 3% BSA in 1X PBS. Wells
were incubated with mouse anti-P30/SAG1 antibody for one hour, then washed with PBS (Table
2). Cells were permeabilized with 0.2% Triton X-100 in 3% BSA then washed with 1X PBS.
Next, cells were incubated with rabbit anti-Toxoplasma antibody for one hour at room
temperature, then washed with 1X PBS (Table 2). Wells were incubated with goat anti-mouse
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Alexa Fluor 488 and goat anti-rabbit Alexa Fluor 594 (Thermo A11012, 1:5000) for one hour in
the dark at room temperature. Wells were washed with 1X PBS, then mounted face down onto a
microscope slide with VECTASHIELD Antifade Mounting Medium and viewed under a
fluorescent microscope. The number of parasites were counted in ten random fields of view.
Dual colored parasites were counted as extracellular, and red parasites were counted as
intracellular. One thousand total parasites were counted for each treatment. The efficiency of
invasion was calculated as the percentage of intracellular parasites out of the total number of
parasites. Invasion assays were performed in triplicate.
TBP DNA Binding Domain Alignment
Protein alignment of the TBP DNA binding domain was conducted with Clustal Omega
(version 1.2.4) multiple sequence alignment (57). Amino acid sequences used for protein
alignment of the TBP DNA binding domain are as follows: Homo sapiens TBP (Uniprot entry
P20226, aa 162-338), Saccharomyces cerevisiae TBP (Uniprot entry P13393, aa 64-239),
Plasmodium falciparum TBP (PlasmoDB entry PF3D7_0506200, aa 150-325), Toxoplasma
gondii TBP1 (ToxoDB entry TGGT1_291080, aa 66-280) and TBP2 (ToxoDB entry
TGGT1_258680, aa 299-547).
Modeling of TgTBP1 and TgTBP2 DNA Binding Domain
The predicted structure of the Toxoplasma TBP1 and TBP2 DNA binding domains were
obtained using I-TASSER using the default setting without any restraints or templates (58,59).
Results were visualized using UCSF Chimera (60)
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Phylogenetic Analysis
TBP and TBP-like factor amino acid sequences were obtained from UniProt and
VEuPathDB (25). Phylogenetic history was inferred using the Maximum Likelihood method and
JJT matrix-based model (61). Evolutionary analysis was conducted in MEGA11, with branch
lengths measured in the number of substitutions per site (62). The tree with the highest log
likelihood was utilized.
Statistical Analysis
ImageJ was used to analyze plaque assay data. To do this, threshold color was used to fill
in all white plaques, and the total plaque number and plaque area were calculated for each well.
The average plaque area was used to determine percent host cell lysis. RStudio was used to
prepare graphical images. Student’s paired t-tests were conducted for replication and invasion
assays with α=0.05.
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CHAPTER III: RESULTS
Conservation, protein modeling, and phylogeny of TgTBP1 and TgTBP2
TgTBP1 is predicted to be a 31.5 kDa size protein possessing a C-terminal DNA-binding
domain consistent with TBPs but containing a gap within the domain. TgTBP2 is predicted to be
a 58 kDa size protein also containing a C-terminal DNA-binding domain consistent with TBPs.
TgTBP1 and TgTBP2 contain 19.5% sequence similarity. TBP uses a string of positively
charged lysine and arginine residues to interact with the phosphate groups on DNA, and four
phenylalanine residues to bend the DNA. As the DNA becomes bent, the DNA-protein
interaction becomes enhanced. Firstly, our goal was to determine if TgTBP1 and TgTBP2
possess these important residues and share structural similarities with other TBPs.
The DNA binding domains of TgTBP1 and TgTBP1 were compared to TBP DNA
binding domains from H. sapiens (Uniprot ID P20226, amino acids 162-338), S. cerevisiae
(Uniprot ID P13393, amino acids 64-239), and P. falciparum (PlasmoDB ID PF3D7_0506200,
amino acids 150-325) (Figure 5A). TgTBP1 possesses 0 of 3 arginine, 1 of 2 lysine and 4 of 4
phenylalanine residues, and TgTBP2 contains 2 of 3 arginine, 1 of 2 lysine, and 3 of 4
phenylalanine residues which are important for direct DNA-protein interaction. While TgTBP1
and TgTBP2 are missing some important residues, structural modeling predicts saddle-like
structures similar to other TBPs (Figure 5B).
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Figure 5. (A) Alignment of the DNA binding domains of TBPs in T. gondii, P. falciparum, H. sapiens, and S. cerevisiae.
Lysine (orange), arginine (yellow), and phenylalanine (blue) residues important for TBP-DNA interaction are highlighted. (B)
Structural prediction of TgTBP1 (top, pink) and TgTBP2 (bottom, orange) aligned with H. sapiens TBP (blue) showing
important DNA-binding residues.

A phylogenetic tree was constructed based on homology on TBPs and TBP-like factors
(TLF) from metazoans, nematode, yeasts, Kinetoplastids, and Apicomplexans using the
Maximum Likelihood method (Figure 6). Many Apicomplexan and Kinetoplastid TBPs relate
more closely to canonical TBPs, including TgTBP2, which has close relation with TBP
homologs in Coccidians (Figure 6). TgTBP1 and its homologs in Apicomplexans diverge from
TBPs and TLFs. These proteins contain residues found in TBPs as well as TLFs, but do not
distinctly relate to one specific group of proteins (Figure 6). TLFs typically possess 1 of 4
phenylalanine residues, 1 of 3 arginine residues, and 0 of 2 lysine residues important for DNA
interaction in canonical TBPs. TgTBP1 possesses all four phenylalanine residues and one of two
lysine residues significant for DNA binding.
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Figure 6. Phylogenetic tree of TBPs and TBP-like factors (TLFs) constructed with the Maximum Likelihood method. Protein sequences
were collected from Uniprot and VEuPathDB from metazoans, nematodes, yeasts, Kinetoplastids, and Apicomplexans. Colors denote group
of organisms. TgTBP1 and TgTBP2 are highlighted in boxes.

DNA binding capability of TgTBP1 and TgTBP2
To assess the DNA binding capability of TgTBP1, a plasmid construct was made to
express a recombinant TgTBP1 protein fused to an N-terminal GST tag. PCR-amplification of
TgTBP2 cDNA was attempted to express recombinant TgTBP2 protein but was unsuccessful.
PCR-amplification of tgtbp1 cDNA containing the coding region was successful and cloned into
the pGEX-4T-1 expression plasmid. The plasmid was transformed into BL21 (DE3) E. coli, and
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GST-TgTBP1 protein expression was induced using IPTG. The recombinant protein was purified
by FPLC for use in EMSAs (Figure 7A). Probes used in initial EMSA experiments included
regions of the dense granule protein gra1 and surface antigen protein sag1 promoters,
approximately 40 base pairs upstream of their transcriptional start sites, and a human TATA-box
sequence from the histone H2B gene. A random DNA sequence was included as a control. Gel
shift assays with recombinant TgTBP1 and these probes yielded no DNA-protein binding (Figure
7B). In our next set of EMSA experiments, four tiled probes in region of the GRA1 promoter
were used in EMSA experiments surrounding the transcriptional start sites. These experiments
yielded no DNA-protein binding. Additionally, nuclear extracts were isolated from ∆Ku80
parasites and combined with the tiled GRA1 DNA oligonucleotides in EMSA experiments. No
binding was observed with nuclear extracts, indicating that no nuclear proteins bound to our
chosen gra1 tiled probes. (Figure 7C).

Figure 7. (A) Purified recombinant TgTBP1 protein on a Coomassie stained gel, shown with an arrow at
52kDa. (B) Gel-shift assay with EBNA control reactions (left) and TgTBP1 recombinant protein with
GRA1, SAG1, H2B, and random (RDM) probes. (C) Gel-shift assays with EBNA control reactions (left)
and nuclear extract with tiled GRA1 and RDM probes.
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Determining the interactome of TgTBP1 and TgTBP2
To determine the interactome of TgTBP1, a parasite line was generated with TurboID
fused to TgTBP1 at its gene locus. The C-terminal end of tgtbp1 gDNA was cloned into a
plasmid construct containing a TurboID-V5-HA tag and an HXGPRT selection cassette. The
plasmid was linearized and transfected into parasites to fuse a C-terminal TurboID-V5-HA tag at
the endogenous tgtbp1 gene locus by single crossover homologous recombination (Figure 8A).
The 3’ end of tgtbp1 in the plasmid construct matches the tgtbp1 endogenous gene and integrates
along with the TurboID-V5-HA tag upstream of the genes stop codon.
TurboID is a biotin ligase engineered from directed evolution of the E. coli biotin ligase
BirA (63). When a protein is fused to TurboID, and with the addition of biotin to the medium,
TurboID converts biotin and ATP to biotin-AMP, a reactive intermediate which covalently labels
any proteins in proximity to the protein with biotin. The TurboID-HA-V5 tag was successfully
integrated at the tgtbp1 gene locus with validation using qRT-PCR. However, the HA tag could
not be detected by IFA or Western Blot. Additionally, TgTBP1-TurboID-HA-V5 parasites were
incubated in biotin and blotted with streptavidin-HRP to detect biotinylated proteins with
Western Blotting. However, no significant biotin labelling was detected by Western Blot.
Transcript levels of tgtbp1 does not change between parental ∆Ku80 and TgTBP1-TurboID-HAV5 parasites, but a 500-fold change increase of TurboID expression is observed in TgTBP1TurboID-HA-V5 parasites compared to ∆Ku80 parasites (Figure 8B). This signifies that there
was successful integration of TurboID at the tgtbp1 locus and no copies of tgtbp1 are present.
The TurboID-HA-V5 tag may be cleaved upon TgTBP1 protein production.
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Figure 8. (A) Tagging strategy for integrating the TurboID-V5-HA tag at the tgtbp1 locus. A plasmid containing tgtbp1
gDNA fused to a TurboID-V5-HA tag and an HXPRT selection cassette was linearized at the 5’ end of tgtbp1. Using single
crossover homologous recombination, the plasmid was integrated directly into the tgtbp1 gene locus by Nucleofection. (B)
Fold change expression of TgTBP1 and TurboID of the TgTBP1-TurboID-V5-HA parasite line by qRT-PCR. Data
normalized against ∆Ku80 parental parasites.

Tetracycline Inducible Knockdown of TgTBP1
To produce a tetracycline inducible knockdown of TgTBP1, a parasite line was generated
replacing the tgtbp1 promoter with a tetO7Sag4 promoter. To do this, the N-terminal end of
tgtbp1 gDNA was cloned into a plasmid containing an upstream tetO7Sag4 promoter, N-terminal
myc tag, and a DHFR selection cassette. Using single crossover homologous recombination, the
promoter was integrated at the tgtbp1 locus replacing the endogenous promoter (Figure 9A). The
5’ end of tgtbp1 sequence in the plasmid construct matches the beginning of the endogenous
tgtbp1 sequence, integrating the tetracycline-regulatable promoter and myc tag at the tgtbp1 gene
upstream of the stop codon. Integration of the tetracycline-regulatable promoter at the tgtbp1
locus was confirmed by genomic PCR (Figure 9B).
Next, the inducible knockdown system was tested to determine when TgTBP1 expression
and protein production was decreasing. In normal growth conditions, a tetracycline-controlled
trans activator (TATi), present in the TATi parental parasite line, binds to the TRE, promoting
normal expression of TgTBP1. When anhydrotetracycline (ATc), a derivative of tetracycline, is
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added to the parasites, it binds to TATi, therefore blocking expression of TgTBP1 (Figure 9D).
ATc was added to parasites over a course of forty-eight hours. Western blotting, IFA, and qRTPCR were performed to determine the loss of TgTBP1 expression and protein levels upon
addition of ATc. The myc-tag signal could not be detected by IFA or Western blot with or
without ATc. qRT-PCR showed a significant fold change decrease in TgTBP1 expression upon
48 hours of incubation with ATc (Figure 9C), demonstrating loss of TgTBP1. The myc tag could
have been cleaved upon protein production.

Figure 9. (A) Promoter replacement strategy to replace the endogenous tgtbp1 promoter with a tetracycline-regulatable promoter. A
plasmid construct was made with the 5’ end of tgtbp1 gDNA fused to a tetracycline-regulatable promoter and myc tag at the Nterminal end. The promoter was replaced by single crossover homologous recombination. (B) Confirmation of integration of the
tetracycline-regulatable promoter in tet-myc-TgTBP1 parasites by genomic PCR. (C) Fold change expression of tgtbp1 -/+ ATc,
showing a significant decrease in tgtbp1 upon the addition of ATc by qRT-PCR determined by paired students t-test. Data normalized
to -ATc parasites, across three biological replicates. (D) Tetracycline inducible knockdown system. In normal growth conditions, a
tetracycline controlled transactivator (TATi) binds to the tetracycline response element (TRE) in the promoter, promoting normal
expression of tgtbp1. Upon addition of ATc, it binds to the TATi and not the TRE, inhibiting tgtbp1 expression.

TgTBP1 knockdown is lethal to parasites
To determine the effect of TgTBP1 loss on parasite growth, plaque assays were
conducted, which analyze the overall parasite lytic cycle. Extracellular parasites invade host
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cells, replicate, then lyse host cells as they egress. Plaques form when host cells are lysed.
Plaque assays were performed with parental controls and knockdown. Parasites do not form
plaques with loss of TgTBP1, showing that TgTBP1 is essential for parasite growth (Figure
10A). Average plaque area data shows no significant difference between controls; a significant
decrease in percent host cell lysis is observed upon TgTBP1 knockdown (Figure 10B).

Figure 10. (A) Intracellular plaque assay of parental TATi parasites +/- ATc and tet-myc-TgTBP1 +/- ATc, demonstrating no
plaque growth upon TgTBP1 knockdown. HFF cells stained with Crystal Violet. Representative of one biological replicate. (B)
Average percent host cell lysis from intracellular plaque assays of TATi parasites +/-ATc and tet-myc-TgTBP1 parasites +/- ATc.
Representative of three biological replicates. Images were analyzed using ImageJ.

To determine how parasite replication is affected by loss of TgTBP1, parasite replication
assays were conducted. Toxoplasma tet-myc-TgTBP1 knockdown and control parasites were
pretreated with and without ATc for twenty-four hours, then were incubated in four wells each
and fixed every twelve hours for an additional forty-eight hours. The number of parasites in 100
separate vacuoles were counted for each treatment. Loss of TgTBP1 resulted in slower parasite
replication over 48 hours of growth (Figure 11A). There is a significant difference in average
parasites per vacuole at 24 and 48 hours of replication across three biological replicates, showing
a delay in parasite replication (Figure 11B).
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Figure 11. (A) Parasite replication assay of tet-myc-TgTBP1 parasites +/- ATc at 12, 24, 36, and 48 hours of growth, representative of
one biological replicate. The number of parasites in 100 vacuoles was counted for each treatment. (B) Average parasites per vacuole of
tet-myc-TgTBP1 parasites +/- ATc in three biological replicates, demonstrating a significant decrease in replication at 24 and 48 hours
upon TgTBP1 knockdown determined by a student’s t-test.

Invasion assays were performed to determine the effect of TgTBP1 knockdown on host
cell invasion. Tet-myc-TgTBP1 control and knockdown parasites were incubated without and
with +ATc respectively for 36 hours then inoculated into fresh host cells with a coverslip.
Parasites were allowed to invade for two hours, then were fixed, blocked, and probed with an
anti-SAG1 antibody with a green fluorophore to target extracellular parasites. The cells were
permeabilized, then probed with an anti-Toxoplasma antibody with a red fluorophore to target
both extracellular and intracellular parasites. Dual-colored parasites were counted as
extracellular, and red colored parasites were counted as intracellular for 1000 total parasites.
Control parasites showed a normal rate of invasion, and upon TgTBP1 knockdown, a 55%
decrease in invasion is observed, demonstrating a significant defect in host cell invasion upon
loss of TgTBP1 (Figure 12).
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Figure 12. Parasite invasion upon TgTBP1 knockdown. One thousand vacuoles were counted for each
treatment and each replicate. Percent invasion is normalized to tet-myc-TgTBP1 parasites -ATc. Across three
biological replicates, a significant decrease in invasion is observed upon TgTBP1 knockdown determined by
a student’s paired t-test.

TgTBP1 knockdown does not affect cell division or morphology
To provide further insight on the role of TgTBP1 in Toxoplasma, cell division and
morphology upon TgTBP1 knockdown was investigated. Tet-myc-TgTBP1 parasites were
incubated with and without ATc for thirty-six hours and IFAs were performed on acetylated-αtubulin, which marks the surface of microtubules. Four stages of the Toxoplasma cell cycle were
observed: interphase, S phase, mitosis, and cytokinesis (Figure 13) (64). No morphological
differences were observed in Toxoplasma parasites upon TgTBP1 knockdown. Additionally,
there was no significant halt in cell cycle progression with addition of ATc (Figure 13).
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Figure 13. (A) Four stages of Toxoplasma cell division: interphase, where parasites are about to begin dividing, S phase, where
daughter cells begin to form within the mother cell, mitosis, where daughter cells are actively beginning to split apart, and
cytokinesis, where the two daughter cells separate. (B) Quantification of each cell cycle stage with (+ATc) and without (-ATc)
TgTBP1 knockdown. Fifty vacuoles were counted for each treatment, and the cell phase was noted for each vacuole.

TgTBP1 knockdown affects tgtbp2 expression
To determine how tgtbp2 expression is affected by loss of TgTBP1, qRT-PCR was
performed on samples incubated with and without ATc for 48 hours. RNA was isolated and
cDNA was prepared, then qRT-PCR was performed using tgtbp2-specific primers. Preliminary
data shows an increased fold change in tgtbp2 expression upon knockdown of TgTBP1 for 48
hours compared to control parasites, whereas tgtbp1 fold change expression decreases (Figure
14).

Figure 14. Preliminary qRT-PCR results demonstrating a decrease in tgtbp1 fold
change expression and an increase in tgtbp2 fold change expression upon
incubation with ATc for 48 hours. Representative of one biological replicate.
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CHAPTER IV: DISCUSSION
Conservation and phylogeny of TBPs in Toxoplasma
The goal of this research was to gain information on the essentiality, DNA binding
capabilities, and protein interactions of TgTBP1 and TgTBP2. Structural predictions of TgTBP1
and TgTBP2 predicted structures similar to the canonical TBP; additionally, many of the
residues needed for direct DNA interaction in TBPs are present in TgTBP1 and TgTBP2 (Figure
5). Although a few key residues are missing in TgTBP1 and TgTBP2, this is also the case for
organisms such as P. falciparum, whose TBP has been shown to bind DNA by EMSA and ChIP
experiments (44,45). In fact, TgTBP2 contains the same DNA-interacting residues as P.
falciparum, making it likely that TgTBP2 also has DNA binding capability. Additionally,
phylogenetic analyses of TgTBP1 and TgTBP2 compared to TBPs and TBP-like factors (TLF)
suggest that TgTBP2 is more closely related to canonical TBPs (Figure 6). TgTBP1 diverges
with a subset of other TBP1 orthologs in select apicomplexans separately from canonical TBPs
and TLFs. The function of TLFs are not well understood, but they are known to be involved in
transcription initiation in other eukaryotes (65). TgTBP1 possesses residues present in TBPs and
TLFs but diverges from both of these sets of proteins, which may reflect functional differences in
TgTBP1. Since TgTBP1 and TgTBP2 contain many of the important residues required for DNA
binding and relate to TBPs and TLFs, I evaluated the DNA binding capability, interactome, and
essentiality of these proteins in Toxoplasma.
DNA binding capability of TgTBP1
To evaluate the DNA binding properties of TgTBP1 and TgTBP2, I aimed to perform
EMSAs on recombinant TgTBP1 and TgTBP2. PCR-amplification of tgtbp2 to create
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recombinant TgTBP2 protein was unsuccessful. Recombinant TgTBP1 was expressed and
purified in E. coli and EMSAs were performed against sequences within two promoter regions in
highly expressed genes in tachyzoites, gra1 and sag1, approximately forty base pairs upstream of
the TSS. A TATA-box sequence from the H. sapiens H2B gene, and a random DNA sequence
were also included. No DNA binding occurred with these probes (Figure 7B). To further explore
the DNA binding capability of TgTBP1, several probes were designed to tile the gra1 promoter
over an approximately 150 base pair range around the TSS. No DNA-protein binding was
observed with recombinant TgTBP1. To ensure that our recombinant protein was not the factor
prohibiting DNA binding, nuclear extracts were prepared and combined with the tiled gra1
probes in gel shift assays. No protein binding was observed with the nuclear extracts (Figure
7C). Due to the lack of DNA binding with our nuclear extract preparation, it is possible that
TgTBP1, TgTBP2, or another transcription factor bind to the gra1 promoter further upstream
from the transcriptional start site to recruit the PIC. TgTBP1 may not bind promoter regions but
other regions of DNA, or does not bind DNA at all, whereas TgTBP2 may be the core DNA
binding element in Toxoplasma based on phylogenetic analyses (Figure 6). Future approaches
for this aim will involve creating transgenic parasite lines with TgTBP1 and TgTBP2 fused to a
3xHA tag. These will allow us to perform CUT&Tag on TgTBP1 and TgTBP2 to determine their
localization throughout the Toxoplasma genome in vivo. Determining the binding sites of
transcription factors in promoter regions could reveal motifs in the Toxoplasma genome.
TgTBP1 is critical for intracellular infection in Toxoplasma
As transcription factors likely involved in initiating gene expression in Toxoplasma, I
hypothesized that TgTBP1 and TgTBP2 are essential for parasite viability. To assess the
essentiality of these proteins in Toxoplasma, a transgenic parasite line was created replacing the
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tgtbp1 promoter with a tetracycline-regulable promoter. The regulatable promoter was
successfully integrated at the tgtbp1 locus (Figure 9B) confirmed by genomic PCR and
knockdown of tgtbp1 expression was confirmed by qRT-PCR (Figure 9C). However, the Nterminal myc tag could not be detected by IFA or Western blot; therefore, it is likely that the myc
tag was cleaved upon protein production, or the tag is inaccessible for antibody binding. I
confirmed that TgTBP1 is essential for parasite growth through intracellular plaque assays,
which assess the overall lytic cycle of the parasite and how it is able to successfully invade,
replicate, and egress from host cells (Figure 10). To look deeper into the role of TgTBP1 in the
parasite lytic cycle, parasite doubling assays were conducted to determine the effect of TgTBP1
loss on parasite replication in host cells. I observed a delay in parasite replication at 12, 24, and
36 hours of growth, but replication did not completely halt (Figure 11). To gain more
information about cell cycle progression and cell morphology upon TgTBP1 knockdown, IFAs
were performed probing the surface of microtubules of Toxoplasma parasites before and after
knockdown. Four stages of cell division were observed for each sample. There was no significant
morphological or cell cycle differences in parasites upon loss of TgTBP1 (Figure 13). Parasites
could still successfully divide upon knockdown but take longer to progress through the cell
cycle. Since the parasites could still successfully divide properly upon TgTBP1 knockdown, I
analyzed their ability to invade host cells upon loss of TgTBP1; if the parasites could
successfully replicate and egress from host cells, they could have a defect in host cell invasion,
resulting in parasite death. Invasion assays confirmed that loss of TgTBP1 results in a defect in
invasion; a significant decrease in invasion is observed upon addition of ATc (Figure 12).
Rapid parasite death within several hours TgTBP1 knockdown was not observed, so it is
possible that TgTBP2 is compensating for loss of TgTBP1. To determine if tgtbp2 is upregulated
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to compensate for loss of TgTBP1, I performed qRT-PCR to quantify tgtbp2 transcript levels
during tgtbp1 knockdown. Preliminary data shows that upon loss of tgtbp1, tgtbp2 expression
increases, indicating that TgTBP2 may be attempting to offset for loss of TgTBP1 (Figure 14).
Additional replicates will be performed to confirm the increase in tgtbp2 expression. TgTBP1
and TgTBP2 are both predicted to be essential for tachyzoite fitness based on a genome wide
CRISPR/Cas9 screen, suggesting that these proteins do not have redundant functions. This is
supported by different domain architectures and key residues important for DNA interaction in
TgTBP1 and TgTBP2 (Figure 5). In addition, the formation of dimers by transcription factors is
a common regulatory mechanism of gene expression in eukaryotes (66). TBPs in humans and
yeast form dimers; it is possible that TgTBP1 and TgTBP2 form heterodimers to regulate
transcription initiation and modulate DNA-binding specificity (36). Further investigation into the
protein interactions of these two proteins are needed to determine their regulatory potential.
Interactome of TgTBP1
As essential proteins likely involved in transcription initiation in Toxoplasma, I sought to
identify the proteins directly interacting with TgTBP1 and TgTBP2, predicting that they interact
with factors in the TFIID complex. To do this, I aimed to tag TgTBP1 and TgTBP2 with the
biotin ligase TurboID, which covalently labels any nearby proteins with biotin. The TurboIDV5-HA tag was successfully integrated at the tgtbp1 gene locus (Figure 8B). However, the tag
could not be detected by Western blot or IFA. Additionally, TgTBP1-TurboID-V5-HA tagged
parasites were incubated with biotin and checked for biotinylation of proteins by Western
blotting and IFA; there was no significant biotin labelling observed. The TurboID-V5-HA tag
could have been cleaved upon protein production. Further optimization of the tag will be needed
to use proximity biotinylation labelling for identifying the interactome of TgTBP1. Future
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approaches for this aim will include utilizing the 3x-HA tagged TgTBP1 and TgTBP2 parasite
lines to perform co-immunoprecipitations and mass spectrometry to identify the factors
interacting with the TBPs in Toxoplasma. This will allow us to gain insight into how TgTBP1
and TgTBP2 potentially regulate transcription and recruit the PIC to the promoter.
Summary and Future Directions
Taken together, I show that TgTBP1 is essential for intracellular infection in Toxoplasma
and is important for proper host cell invasion and replication. Future studies on TgTBP1 will
further investigate its DNA binding abilities, interactome, and its role in regulating gene
expression in Toxoplasma. An RNA-sequencing experiment will be performed before and after
knockdown of TgTBP1 to determine its role in global gene expression in the parasite and to
identify the subsets of genes that are regulated by TgTBP1. With this information, we may
narrow down the potential role of TgTBP1 in gene expression and regulation in Toxoplasma.
Additionally, further investigation into the function of TgTBP2 is needed. Future studies will
analyze the interactome, genomic localization, and essentiality of TgTBP2 on parasite viability.
Determining how these two proteins function will provide insight into how RNA polymerases
are recruited to promoters and how gene expression is regulated in Toxoplasma. With this
information, we can identify unique features of these processes that could potentially be targeted
with therapeutic drugs to treat toxoplasmosis.
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APPENDIX
Table 3. Primers utilized in this study for plasmid construction, integration confirmation, and qRT-PCR.
Primer

Sequence 5'-3'

Forward/Reverse?

1

CGTGACGCGATAGTGTTC

Forward

2

GTTAATGGATGGCGCTGC

Reverse

3

GCTGATTCGTGAATCCCTTG

Forward

4

CCTCGCGATCTTCTTCATCG

Reverse

5

CGATGAAGAAGATCGCGAGG

Reverse

6

GGTTCCGCGTGGATCCCCGGAATTCGAAGAGGAGGAAGGCGAAG

Forward

7

CGGCCGCTCGAGTCGACCCGGGAATTCGAACCGTGACGCGATAGTG

Reverse

8

AGCGCGCCCACCGCGGTGGCCTAGGCACAGTGTCCGTGTGGATG

Forward

9

GAGGCACAGTATTGTCTTTAGATCTACTTGTCCCGTTCGCAAC

Reverse

10

AATCTCCGAGGAAGACTTGAGATCTGCGACCACTCGTCAGCAC

Forward

11

TGGAGCTCCACCGCGGTGGCGGCCGCTGTGAGGACCCCGTCTGG

Reverse

12

GGGCTGGCAAGCCACGTTTGGTG

Forward

13

CCGGGAGCTGCATGTGTCAGAGG

Reverse

14

GATTAAGTTGGGTAACGCCAG

Forward

15

CTGTTCGCCACTATGGAAC

Reverse

16

GAGTGGTAAACTCGAGGTCG

Forward

17

ACTGGCCGTCGTTTTACA

Reverse

18

GAAAGCGATCGACACAAACAG

Forward

19

CCGTAGAGAAAAGCTGGAGTG

Reverse

20

GGATTAACGTGGCTATGAGG

Forward

21

CCAGAGTATTCCTGTCCAG

Reverse

22

GAATTCTCCAGCTACGAACCC

Forward

23

TCCCGTAATCACAACCTTGC

Reverse

24

GATGCCCTCTGACAAGACC

Forward

25

CATCCTCTTTCCCGCTGATC

Reverse

Table 4. Biotin-labelled oligos used in EMSA experiments. Probes denote the 5’ to 3’ sequence on the
sense strand; a biotin-labelled reverse complimentary sequence for each probe was annealed for all oligos.
Probe

Sequence 5' to 3' (Sense strand)

GRA1-1

GTGACCACCCCACTTCGCATTGGGCAATCGGTAAAGCCATAACATTACTT

SAG1

CTGTAGTCACTGCTGATTCTCGCTGTTCTCGGCAAGGGCTGACGACC

H2B TATA-Box

CTGAAGCGATTCTATATAAAAGCGCCTTGTCATAC

GRA1-2

CGATAAAATTGCAAAGTAATGTTATGGCTTTACCGATTGCCCAATGCGAAG

GRA1-3

CTCGCTCGGCAGTTTCAACCGATAAAATTGCAAAGTAATGTTATGGCTTT

GRA1-4

AGACAGCACCCAAAAACGCAAGCTCGCTCGGCAGTTTCAACCGATAAAATTG

GRA1-5

TAACTGATAAAAGGTGGGAGAAGACAGCACCCAAAAACGCAAGCTCGCTCGG

Random Sequence

CGAACCTCAGTTGGCCTACATCCTACCTGAGGTCTGTGCC
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